ALLR

Allarity Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on developing oncology therapeutics guided by its proprietary drug response predictor platform. Headquartered in Cambridge, Massachusetts, the company utilizes its DRP® (Drug Response Predictor) technology to identify patients most likely to benefit from its cancer treatment candidates, aiming to improve clinical trial outcomes and personalize cancer care. Allarity's pipeline includes stenoparib, a PARP inhibitor in Phase 2 clinical trials for ovarian cancer and other solid tumors, and dovitinib, a pan-TKI (tyrosine kinase inhibitor) being evaluated for renal cell carcinoma. The company's DRP® platform analyzes gene expression patterns to predict individual patient responses, potentially reducing development costs and accelerating regulatory pathways. Allarity completed its merger with Screen Holdings in 2021 and began trading on Nasdaq under the ticker ALLR. The company maintains operations in Denmark, where much of its research activities originated. As a development-stage enterprise, Allarity generates no product revenue and funds operations through equity financings and strategic partnerships. Recent initiatives include advancing its clinical programs and expanding its DRP® companion diagnostic capabilities to support regulatory submissions and potential commercialization of its oncology candidates.